Proceedings of the National Academy of Sciences of the United States of America

Reducing BIN1 improves nerve damage caused by DNM2-related Charcot-Marie-Tooth disease

Updated

Abstract

Increasing levels worsened symptoms in mice with the most common mutation.

  • Whole-body reduction of BIN1 improved motor performance and muscle organization in mice with a CMT mutation.
  • The beneficial effects of reducing BIN1 persisted for at least 1 year.
  • BIN1 was found to inhibit the activity of DNM2, a protein associated with CMT.
  • Elevated activity of a specific CMT mutant contributed to the observed improvements.
  • The findings suggest a complex relationship between BIN1 and CMT, with potential therapeutic implications.

Simplified

Key numbers

50%
Increase in Motor Performance
Reduction of levels in mice.
100%
Lethality Rate from Overexpression
Survival rates of mice with overexpression.
1 year
Sustained Improvement Duration
Duration of observed benefits in mice post- reduction.

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Competing interests statement:Jocelyn Laporte is inventor on a patent describing BIN1 overexpression to cure centronuclear myopathies.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free